Acquisition accelerates Full-Life’s transformation into a clinical-stage radiopharmaceutical company, building on its European-focused development and radiotechnology platform
BRUSSELS and WATCHUNG, NJ and SHANGHAI, November 29, 2022 /PRNewswire/ — Full-Life Technologies, a fully integrated global radiation therapy company, today announced an agreement to acquire New JerseyBased at Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on patented peptide engineering technology. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide-focused discovery platform, and leverages its Radio Technology manufacturing and logistics platforms to make advance compounds to clinical development.
Under the terms of the acquisition, Focus-X shareholders are eligible to receive from Full-Life an upfront payment, potential development, regulatory and sales-based milestones of up to $245 million and commercial sales royalties. The acquisition is expected to be completed in the first quarter of 2023.
“The acquisition of Focus-X perfectly leverages Full-Life’s radiotechnology and development platform by adding two development-ready compounds, including a leader with early human data, a robust pipeline and peptide discovery capabilities. world-class,” said Lanny SunCo-founder, President and CEO of Full-Life.
Fa Liu, PhD, co-founder and CEO of Focus-X, said, “Full-Life’s integrated platforms will provide the manufacturing technology, logistics and clinical development expertise to accelerate the development of our compounds and expand our discovery efforts. This world-class radiopharmaceutical has enormous potential to develop radiopharmaceutical therapies that impact patients around the world. »
Founded in 2020, Focus-X has developed a proprietary engineering platform to develop peptide radioligands that precisely deliver alpha or beta emitters to break down cancer cell DNA. The platform enables high-quality optimization of peptide radioligand vectors for key pharmaceutical attributes such as biodistribution, binding affinity and live stability. Such optimization can present significant challenges for other ligand targeting compounds such as antibodies. The company focused on both validated targets and novel mechanisms.
Focus-X has established a substantial pipeline. The Company’s two lead compounds in development are a prostate-specific membrane antigen (PMSA)-targeting peptide for the treatment of metastatic castration-resistant prostate cancer and a neurotensin-like receptor-targeting peptide. 1 (NTSR1) for the treatment of pancreatic cancer. The target compound PMSA is currently undergoing an investigator-initiated imaging study. Focus-X has six other programs in earlier stages of development.
About Full-Life Technologies
Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China. We seek to own the entire value chain for radiopharmaceutical research and development, production and commercialization to achieve clinical impact for patients. The company plans to tackle fundamental issues affecting today’s radiopharmaceuticals through innovative research that targets tomorrow’s treatments. We are made up of a dynamic team of entrepreneurs and scientists with a proven track record in life sciences, as well as radioisotope research and clinical development.
SOURCE Full-Life Technologies Limited